Researchers discovered that a protein called DDR2 may help prevent fatty liver disease, a common condition where fat builds up in the liver. Using mice, scientists found that when DDR2 levels were high, the liver stored less fat and made fewer fatty substances. The protein works by turning on special switches in liver cells that tell them to burn fat instead of storing it. This discovery is exciting because fatty liver disease affects millions of people worldwide and currently has no proven medication to treat it. If these findings work in humans, DDR2 could become an important new tool for fighting this disease.
The Quick Take
- What they studied: Whether a protein called DDR2 can reduce fat accumulation in the liver and how it works to do this
- Who participated: Laboratory mice, including genetically obese mice and mice fed high-fat diets, plus liver cells grown in dishes. No human participants were involved in this study.
- Key finding: When DDR2 levels were increased in mice livers, fat buildup decreased significantly. When DDR2 was reduced, fat buildup increased. The protein appears to work by activating special fat-burning switches called AMPK and ACC.
- What it means for you: This research suggests DDR2 might become a new treatment target for fatty liver disease in the future. However, this is early-stage research in animals—much more testing is needed before any human treatments could be developed. If you have fatty liver disease, current lifestyle changes like diet and exercise remain your best options.
The Research Details
Scientists conducted experiments using both living mice and liver cells grown in laboratory dishes. They studied two types of mice: some that were genetically prone to obesity and others that were fed high-fat diets to mimic human eating patterns. The researchers measured DDR2 protein levels in sick and healthy livers, then artificially increased or decreased DDR2 to see what happened to fat storage. They used several techniques to measure results, including staining fat with special dyes and measuring gene activity. This combination of cell and animal studies allowed researchers to understand both how DDR2 works at the molecular level and whether those effects translate to whole organisms.
Using both cell and animal models strengthens the findings because it shows the effect works at multiple levels of biological organization. Testing in mice that naturally develop fatty liver disease (like the genetically obese mice) is important because it mimics the human condition more closely than artificial models. This approach helps researchers understand not just whether something works, but how and why it works.
This study was published in Scientific Reports, a reputable peer-reviewed journal. The researchers used multiple complementary techniques to measure the same outcomes, which increases confidence in the results. However, this is animal research only—findings in mice don’t always translate to humans. The study doesn’t specify exact sample sizes for all experiments, which makes it harder to assess statistical power. This is exploratory research meant to identify a promising target, not definitive proof that DDR2 treatments will work in people.
What the Results Show
The main discovery was that DDR2 protein levels were significantly lower in livers with fatty disease compared to healthy livers. When researchers increased DDR2 in liver cells and mice, triglycerides (a type of fat) accumulated less in the liver tissue. Gene expression tests showed that cells with more DDR2 produced fewer of the proteins involved in making new fat. Conversely, when DDR2 was reduced or removed, the opposite happened—fat accumulated more and fat-making genes became more active. These effects were consistent across both the cell experiments and the whole-animal studies, suggesting the findings are robust.
The mechanism behind DDR2’s effects involves activation of two molecular switches called AMPK and ACC. When DDR2 was increased, these switches became more active (phosphorylated). When researchers used drugs to block AMPK, the beneficial effects of DDR2 disappeared, proving that AMPK activation is essential for DDR2’s fat-reducing ability. This mechanistic finding is important because it identifies the specific pathway through which DDR2 works, which could guide future drug development.
Fatty liver disease has been a major health challenge with no approved medications specifically designed to treat it. Previous research has shown that AMPK activation can help reduce liver fat, but the triggers for activating AMPK in fatty liver disease weren’t well understood. This study identifies DDR2 as a previously unknown activator of AMPK in the liver, filling an important gap in our understanding. The finding that DDR2 is reduced in diseased livers suggests that restoring DDR2 function could be a new therapeutic strategy.
This research was conducted entirely in mice and cell cultures—no human studies were performed. Mice don’t always respond to treatments the same way humans do, so these findings need human testing before any conclusions can be drawn about clinical use. The study doesn’t provide detailed information about sample sizes for all experiments, making it difficult to assess statistical reliability. The research doesn’t examine potential side effects of increasing DDR2, which would be crucial before human trials. Additionally, the study doesn’t compare DDR2 activation to other existing treatments or lifestyle interventions.
The Bottom Line
Current evidence (from animal studies) suggests that therapies targeting DDR2 or the AMPK/ACC pathway may help treat fatty liver disease in the future. However, confidence in this recommendation is low because human studies haven’t been conducted. For now, the most evidence-based approaches for fatty liver disease remain weight loss through diet and exercise, reducing sugar intake, and limiting alcohol. Anyone with fatty liver disease should work with their healthcare provider on these proven strategies while researchers continue developing new treatments.
This research is most relevant to people with metabolic dysfunction-associated steatotic liver disease (MASLD) or non-alcoholic fatty liver disease (NAFLD), which affects roughly 25-30% of adults worldwide. It’s also relevant to researchers and pharmaceutical companies developing new treatments. People without liver disease don’t need to take action based on this research. Those with fatty liver disease should be aware that promising new treatments are in development but shouldn’t delay implementing proven lifestyle changes.
This is very early-stage research. Even if DDR2-based treatments prove effective in humans, it typically takes 10-15 years from basic research discovery to FDA approval of a new medication. Realistic expectations: this research may lead to clinical trials within 3-5 years if funding and development progress well, but patients shouldn’t expect DDR2 treatments to be available soon. Lifestyle changes can show benefits within weeks to months and remain the most immediately actionable approach.
Want to Apply This Research?
- Track liver health markers: record weight, waist circumference monthly, and note any fatigue or abdominal discomfort. If your healthcare provider orders liver function tests, log the results (ALT, AST, and triglyceride levels) to monitor trends over time.
- Use the app to set and track daily goals for liver-friendly habits: aim for 150 minutes of moderate exercise weekly, reduce added sugar intake to under 25g daily, and maintain a consistent sleep schedule. Log meals to identify high-fat and high-sugar foods to reduce.
- Create a quarterly check-in reminder to review trends in your tracked metrics. Set alerts for research updates about DDR2 and fatty liver disease treatments so you stay informed as new developments emerge. Share your tracked data with your healthcare provider during regular checkups to monitor disease progression and adjust lifestyle interventions as needed.
This research describes early-stage laboratory and animal studies only. DDR2-based treatments are not yet available for human use and have not been tested in clinical trials. This information is for educational purposes and should not be considered medical advice. If you have or suspect you have fatty liver disease, consult with a qualified healthcare provider for proper diagnosis and treatment. Current evidence-based treatments include lifestyle modifications such as weight loss, dietary changes, and exercise. Do not attempt to self-treat based on this research or delay seeking professional medical care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.